identified as being critical dosage-sensitive genome for cardiac development and have also emerged as important contributors to CHDs. Examples of this include the TBX1 deletion at 22q11.2, the GATA4 deletion at 8p23.1, and the NKX2-5 deletion at 5q35.1. 3, 4 An increasing assortment of CNVs affecting cardiac-related genes have been detected in individuals with CHDs. Recent population studies indicate that the 22q11.2 deletion is the most common microdeletion syndrome, occurring in 1 per 5950 live births and nearly 0.5%-1.9% of all CHDs, 5 usually arising de novo, which accounts for 34% of truncus arteriosus and 16% of tetralogy of fallot (TOF) cases. 6 Previous studies have identified that GATA4, NKX2.5, and TBX5 contribute to monogenic forms of CHD, 7, 8 while BMP4 and CRELD1 are closely related to the development of CHD.
Inactivation of BMP4 within the myocardium results in neonatal lethality results in severe defects in septation and valve diseases such as ASD and VSD. 9 CRELD1 gene can cause CHD in Down syndrome-atrioventricular septal defect (AVSD) and also in sporadic forms of AVSD without any syndromic features. 10 However, combined mutation screening revealed that congenital heart defects are rarely caused by mutations in these genes. 11 Thus far, no study has been conducted to investigate the role of NKX2.5, TBX5, BMP4, and CRELD1 CNVs in Chinese children with sporadic congenital heart disease, we analyzed a cohort of 167 patients with sporadic cardiac anomalies using multiplex ligation-dependent probe amplification (MLPA) and copy number variation sequencing (CNV-Seq).
| ME THODS

| Materials and methods
The study cohort enrolled 167 patients after an ultrasound diagnosis with unselected CHD at the Liuzhou Maternal and Child Healthcare Hospitals, Guangxi, southwest China between 2012 and 2016. All the patients in this study had no history of CHD in first-degree relatives. Congenital cardiac malformations were diagnosed by echocardiography and subsequently confirmed during surgery when performed. Extra-cardiac findings were extracted from medical records and included dysmorphic features, major anomalies, noncardiac medical problems, and deficiencies in growth or developmental delay. This study was approved by the Liuzhou maternal and children healthcare hospital ethics review board on human subjects.
All the patients were assessed by MLPA and CNV-seq.
| MLPA analysis
Genomic DNA was extracted from peripheral blood by phenol/chloroform extraction and quality determined with a NanoDrop 2000 Sequence deletion or duplication was considered when a 35%-50% variation in the relative peak area of the amplification product of the respective probe was obtained.
| Next generation sequencing
Copy number variation sequencing was performed with next generation sequencing (NGS) as previously described. 12 We constructed 
| RE SULTS
A cohort of 167 patients with sporadic CHD were enrolled. CHD phenotypes included ventricular septal defect (VSD, n = 121), atrial septal defect (ASD, n = 24), TOF, (n = 12), VSD combined with TOF (n = 6), patent ductus arteriosus (PDA, n = 2), and VSD combined with ASD (n = 2). The ages of the patients ranged from 2 months to 17 years, while the mean age was 2.8 years.
Among these 167 CHD patients, no imbalances were detected in any of the GATA4, NKX2-5, TBX5, BMP4, or CRELD1 exons. Associated with the 22q11 region, the MLPA assay detected a heterozygous deletion in the CDC45, GP1BB, and DGCR8 genes ( Figure 1 ). Of the 5 patients with a 22q11 region deletion, two were diagnosed with VSD and ASD, one had VSD, and one other was diagnosed with TOF. The specific type of cardiac defect and hemodynamic status identified in the 6 patients is shown in Table 1 Table 2 . First-degree relatives of the patients in this study had no history of CHD and negative for the abnormal CNV. 
F I G U R E 1 Multiplex ligation-dependent probe amplification (MLPA) analysis. A, Normal control. B, Positive for deletion of the CDC45, GP1BB, and DGCR8 probes located in 22q11 region (red dots)
| D ISCUSS I ON
Genetic causes of CHDs include structural abnormalities of the chromosome and gene dosage disorders. There is accumulating evidence indicating that a number of genomic disorders are strongly associated with gene dosage and the development of CHDs. 13 Determining which CNVs contribute toward disease is an issue that is worth studying. With the development of genetic testing for CHDs, CNVs play an important role in diagnosis and gene discovery. 14 Characteristics of a pathogenic CNV may include abnormalities in a known diseaseassociated regions, or gene dosage irregularities. 15 These may therefore be observed in individuals with cardiovascular malformations.
As molecular targets for CHD, MLPA was used to screen the This is close to the 2.56% found by Campos et al. 17 An abundance Unlike the 22q11 deletion, duplications in this region are rarely reported. 21 Less is known about the highly variable phenotype linked to these duplications, 22 but it appears to be associated with elevated rates of ASD and delays in language and psychomotor development. 23 In the present study, we detected a 0. Secondly, this duplication is frequently inherited and we failed to verify its presence in the family. Further investigation into this finding is thus required.
The 167 patients used in this study were initially characterized by CNV-seq and MLPA. Using MLPA, five of the patients (Table 1) 
| CON CLUS ION
In summary, our results suggest that deletions in the 22q11. 
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